Boehringer Ingelheim Vienna €700 m (2021), Novartis/Sandoz Schaftenau (2024), Sandoz Kundl.
Cross-border GMP fit-out workforce mobilisation against Boehringer Ingelheim Vienna €700 m cell-culture plant (inaugurated October 2021), Novartis/Sandoz Schaftenau €250 m biopharmaceuticals plant (opened 2024), Sandoz Kundl €100 m+ enzymatic oral-amoxicillin line + 3-floor building (~1,875 m² completion early 2024), and the BioNEX Bruck/Leitha programme (€1.2 bn, paused Q1 2023) — AGES + BASG, EU GMP Annex 1 (2022).
Request Technical BriefingRegulator exposure profile
- AGES / BASG + EU GMP Annex 130%
- AGH + LSD-BG + ZKO24%
- BUAK + KV-Pharma24%
- ÖNORM EN ISO 1464422%
Pressure-cascade direction is the proof.
EU GMP Annex 1 (2022) positive-pressure cascade A → B → C → D. BASG/AGES verifies cascade direction at on-site inspections; ÖNORM EN ISO 14644 particle counts.
▲ Grade A · +30 Pa (Boehringer Vienna fill)
- A fulfilled
Aseptic processing
- +30 Pa target
- ISO Class 5 in-operation
- Microbial < 1 CFU/m³
- B fulfilled
Surrounding Grade A
- +15 Pa target
- ISO Class 7 in-operation
- C partial
Clean preparation
- +5 Pa target
- D unfulfilled
Support
- Ambient
▼ Grade D · ambient
Named projects in this jurisdiction
- Boehringer Ingelheim Vienna cell-culture plant (€700 m, inaugurated October 2021) Boehringer Ingelheim 2021
- Novartis/Sandoz Schaftenau biopharmaceuticals plant (€250 m, opened 2024) Novartis / Sandoz 2024
- Sandoz Kundl (€100 m+ enzymatic oral-amoxicillin line, ~1,875 m² 3-floor building, early 2024) Sandoz / Novartis 2024
- Boehringer Ingelheim BioNEX Bruck/Leitha (€1.2 bn, paused Q1 2023) Boehringer Ingelheim
Austria’s pharma cluster centres on Vienna (Boehringer Ingelheim), Tirol (Sandoz Kundl, Novartis Schaftenau). BASG holds federal manufacturing authorisation; AGES is the parent agency.
01. Pre-pricing — KV-Pharma + BUAK
Process workforce at KV-Pharma (Pharmaindustrie tariff). Civil shell at BUAK.
02. ZKO-Meldung + A1 + GMP Annex 1 + BASG documentation
A1 + German-language contract + ZKO-Meldung predate site arrival. BASG/AGES verifies Annex 1 cascade.
03. BUAK + KV-Pharma onboarding
Civil portion at BUAK. Process portion at KV-Pharma.
04. Finanzpolizei + Arbeitsinspektion + BASG-defensible evidence pack
Minimum pack: SEPA-traceable remuneration, German-language contract, ZKO record, BUAK / KV-Pharma membership, GMP gowning per Grade A/B individual.
05. India and Gulf sourcing corridors — the AT GMP pathway
Indian pharma-trade pool through ISPE-affiliated GMP-trained fitters. The 8 to 14-week corridor delivers candidates against Boehringer Vienna, Novartis Schaftenau, or Sandoz Kundl.